DK2032156T3 - Sammensætninger og fremgangsmåder til levering af oxygen - Google Patents

Sammensætninger og fremgangsmåder til levering af oxygen

Info

Publication number
DK2032156T3
DK2032156T3 DK07795174.7T DK07795174T DK2032156T3 DK 2032156 T3 DK2032156 T3 DK 2032156T3 DK 07795174 T DK07795174 T DK 07795174T DK 2032156 T3 DK2032156 T3 DK 2032156T3
Authority
DK
Denmark
Prior art keywords
procedures
compositions
delivering oxygen
delivering
oxygen
Prior art date
Application number
DK07795174.7T
Other languages
Danish (da)
English (en)
Inventor
Emily Weinert
Jonathan A Winger
Stephen P L Cary
Michael A Marletta
Elizabeth M Boon
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2032156T3 publication Critical patent/DK2032156T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07795174.7T 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen DK2032156T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
PCT/US2007/012184 WO2007139791A2 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of oxygen

Publications (1)

Publication Number Publication Date
DK2032156T3 true DK2032156T3 (da) 2013-02-18

Family

ID=38779160

Family Applications (4)

Application Number Title Priority Date Filing Date
DK07795174.7T DK2032156T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen
DK11189807.8T DK2463294T3 (en) 2006-05-22 2007-05-21 Compositions and Methods for Delivery of Nitric Oxide
DK07795153.1T DK2040740T3 (en) 2006-05-22 2007-05-21 COMPOSITIONS AND PROCEDURES FOR DELIVERING NITROGEN MONOXIDE
DK11189814.4T DK2463297T3 (en) 2006-05-22 2007-05-21 Oxygen Compositions and Methods

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK11189807.8T DK2463294T3 (en) 2006-05-22 2007-05-21 Compositions and Methods for Delivery of Nitric Oxide
DK07795153.1T DK2040740T3 (en) 2006-05-22 2007-05-21 COMPOSITIONS AND PROCEDURES FOR DELIVERING NITROGEN MONOXIDE
DK11189814.4T DK2463297T3 (en) 2006-05-22 2007-05-21 Oxygen Compositions and Methods

Country Status (12)

Country Link
US (7) US8404632B2 (enExample)
EP (7) EP2463294B1 (enExample)
JP (5) JP5698906B2 (enExample)
CN (5) CN104689300B (enExample)
AU (2) AU2007268052B2 (enExample)
BR (2) BRPI0711901A2 (enExample)
CA (2) CA2653080C (enExample)
DK (4) DK2032156T3 (enExample)
ES (4) ES2399662T3 (enExample)
IN (2) IN2013MN00601A (enExample)
NZ (4) NZ594457A (enExample)
WO (2) WO2007139791A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
EP3922643A1 (en) 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
SG10201908269SA (en) * 2015-03-17 2019-10-30 Omniox Inc Modulation of tumor immunity by protein-mediated o2 delivery
BR112018016829A2 (pt) * 2016-02-16 2018-12-26 Omniox Inc método para tratar acidente vascular cerebral em um indivíduo, método para administrar oxigênio a um indivíduo, método para tratar um ataque isquêmico transitório em um indivíduo, método para tratar uma lesão cerebral hipóxica em um indivíduo, composição, composição farmacêutica, uso de uma composição, kit e método para preparar uma composição
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
WO2020037052A1 (en) 2018-08-15 2020-02-20 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
KR102776925B1 (ko) 2019-06-25 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
PH12022551441A1 (en) 2019-12-24 2023-11-20 Carna Biosciences Inc Diacylglycerol kinase modulating compounds
CR20220396A (es) 2020-02-14 2022-11-14 Jounce Therapeutics Inc Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
US20240043427A1 (en) 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
AU6766994A (en) 1994-04-01 1995-10-23 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
JP4583510B2 (ja) * 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 無細胞系による酸素輸送の最適化のための方法と組成物
WO1998050430A2 (en) 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) * 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
ATE553782T1 (de) * 1999-12-22 2012-05-15 Scripps Research Inst Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
CA2410953A1 (en) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP4873860B2 (ja) * 2002-08-30 2012-02-08 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide

Also Published As

Publication number Publication date
BRPI0711901A2 (pt) 2012-03-06
ES2611157T3 (es) 2017-05-05
CN101495134A (zh) 2009-07-29
NZ573004A (en) 2012-06-29
CA2653080A1 (en) 2007-12-06
CN101495506A (zh) 2009-07-29
WO2007139791A2 (en) 2007-12-06
EP2040740A2 (en) 2009-04-01
EP2032156A2 (en) 2009-03-11
DK2040740T3 (en) 2014-12-01
US20130289252A1 (en) 2013-10-31
JP2014224156A (ja) 2014-12-04
IN2013MN00601A (enExample) 2015-06-12
EP2032156B1 (en) 2012-11-21
CN101495134B (zh) 2016-08-03
EP2474554A3 (en) 2012-10-03
JP6118772B2 (ja) 2017-04-19
US9493526B2 (en) 2016-11-15
EP2040740A4 (en) 2009-10-21
EP2463294B1 (en) 2016-10-19
JP2015007108A (ja) 2015-01-15
ES2610653T3 (es) 2017-04-28
EP2463297A1 (en) 2012-06-13
JP2009538133A (ja) 2009-11-05
CA2653101C (en) 2016-12-13
JP2017137337A (ja) 2017-08-10
EP2463295A1 (en) 2012-06-13
JP5698906B2 (ja) 2015-04-08
US8404631B2 (en) 2013-03-26
AU2007268028A1 (en) 2007-12-06
HK1129688A1 (en) 2009-12-04
EP2463296A1 (en) 2012-06-13
CA2653101A1 (en) 2007-12-06
BRPI0711767B1 (pt) 2018-05-15
US8404632B2 (en) 2013-03-26
DK2463297T3 (en) 2017-01-09
AU2007268052B2 (en) 2013-07-04
US20100266673A1 (en) 2010-10-21
NZ573003A (en) 2012-06-29
CN106075388A (zh) 2016-11-09
WO2007139767A3 (en) 2008-02-07
EP2474554A2 (en) 2012-07-11
CN101495506B (zh) 2016-08-10
JP5698905B2 (ja) 2015-04-08
CN108273040A (zh) 2018-07-13
EP2032156A4 (en) 2009-11-11
US20170267732A1 (en) 2017-09-21
US10202428B2 (en) 2019-02-12
WO2007139767A2 (en) 2007-12-06
US20150266931A1 (en) 2015-09-24
US20100285104A1 (en) 2010-11-11
JP2009538134A (ja) 2009-11-05
NZ594457A (en) 2013-06-28
CN104689300B (zh) 2018-06-05
DK2463294T3 (en) 2017-01-16
AU2007268028B2 (en) 2013-03-14
US9493527B2 (en) 2016-11-15
CA2653080C (en) 2019-02-12
EP2463294A1 (en) 2012-06-13
ES2399662T3 (es) 2013-04-02
CN104689300A (zh) 2015-06-10
IN2013MN00600A (enExample) 2015-06-12
JP6458070B2 (ja) 2019-01-23
BRPI0711767A2 (pt) 2012-01-10
NZ594456A (en) 2013-06-28
BRPI0711767B8 (pt) 2021-05-25
JP6118296B2 (ja) 2017-04-19
EP2463297B1 (en) 2016-10-19
WO2007139791A3 (en) 2008-05-02
EP2040740B1 (en) 2014-09-03
US20150376250A1 (en) 2015-12-31
AU2007268052A1 (en) 2007-12-06
ES2525226T3 (es) 2014-12-19
CN106075388B (zh) 2021-06-29
US20130288970A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
DK2032156T3 (da) Sammensætninger og fremgangsmåder til levering af oxygen
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK2240155T3 (da) Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2099489T3 (da) Sammensætninger og fremgangsmåder til behandling af en neoplasme
DK2131856T3 (da) Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2334378T3 (da) Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK1991678T4 (da) Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2029746T3 (da) Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
DK3176159T3 (da) 4-phenyl-6-(2,2,2-trifluor-1-phenylethoxy)pyrimidin-baserede forbindelser og fremgangsmåder til anvendelse deraf
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK2114924T3 (da) Co-krystaller og farmaceutiske sammensætninger omfattende disse
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger